Oncothyreon

Merck to continue development of Tecemotide in phase III trial

Tuesday, October 1, 2013 10:30 AM

Merck Serono, the biopharmaceutical division of Merck, has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide  (also known as L-BLP25 and formerly known as Stimuvax). Merck Serono, which is developing tecemotide under a license agreement with Oncothyreon, will conduct a new phase III trial called START2 for patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »

Mymetics ropes in Dendreon vets

Wednesday, April 11, 2012 12:58 PM

Mymetics, a Swiss-based biotech of mucosal and virosomal-based vaccines for infectious diseases, has appointed Grant E. Pickering as president and CEO and Christopher S. Henney as chairman of the board of directors. The changes were made in connection with Mymetics’ efforts to obtain additional financing and to advance the development of its vaccine platform.

More... »

Oncothyreon advances to phase II of PX-866 trial

Thursday, October 20, 2011 11:19 AM

Oncothyreon it has initiated the phase II portion of  its ongoing phase I/II trial of PX-866 in combination with the chemotherapeutic agent  docetaxel (Taxotere) following successful completion of the phase I dose escalation portion  of the study. PX-866 is a small molecule compound designed to inhibit  the activity of phosphatidylinositol-3-kinase (PI-3K), a component of  an important cell survival signaling pathway.

More... »